A Prospective, single-blind, multicenter, dose escalation study of intracoronary iNOS Lipoplex (CAR-MP583) gene therapy for the prevention of restenosis in patients with de novo or restenotic coronary artery lesion (regent i extension)

Human Gene Therapy

Volumn 22, Issue 8, 2011, Pages 951-958

  Von Der Leyen, Heiko E ^a   Mügge, Andreas ^b   Hanefeld, Christoph ^b   Hamm, Christian W ^c   Rau, Mathias ^c   Rupprecht, Hans J ^d   Zeiher, Andreas M ^e   Fichtlscherer, Stephan ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c KERCKHOFF HEART CENTER   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CAR MP 583; CAR MP583; CLOPIDOGREL; HEPARIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPLEX; TROPONIN; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BALLOON CATHETER; CARDIOVASCULAR GENE THERAPY; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CORONARY STENT; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IN-STENT RESTENOSIS; LIPOSOMAL GENE DELIVERY SYSTEM; LOADING DRUG DOSE; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSPECIFIED SIDE EFFECT;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY RESTENOSIS; FEMALE; GENE THERAPY; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD;

ANIMALIA;

EID: 80052005422     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2010.161     Document Type: Article

References (29)

1. Assoian, R.K., and Marcantonio, E.E. (1996). The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J. Clin. Invest. 98, 2436-2439. (Pubitemid 26415061)
2. Barath, P., Popov, A., Dillehay, G.L., et al. (1997). Infiltrator an-gioplasty balloon catheter: a device for combined angioplasty and intramural site-specific treatment. Cathet. Cardiovasc. Diagn. 41, 333-341. (Pubitemid 27283818)
3. Cooney, R., Hynes, S.O., Sharif, F., et al. (2007). Effect of gene delivery of NOS isoforms on intimal hyperplasia and endo-thelial regeneration after balloon injury. Gene Ther. 14, 396-404.
4. Dubey, R.K., Jackson, E.K. and Lüscher, T.F. (1995). Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J. Clin. Invest. 96, 141-149.
5. Fishbein, I., Alferiev, I.S., Nyanguile, O., et al. (2006). Bispho-sphonate-mediated gene vector delivery from the metal surfaces of stents. Proc. Natl. Acad. Sci. U.S.A. 103, 159-164. (Pubitemid 43076121)
6. Garg, S., and Serruys, P.W. (2010a) Coronary stents: current status. J. Am. Coll. Cardiol. 56 (10 Suppl): S1-S42.
7. Garg, S., and Serruys, P.W. (2010b) Coronary stents: forward looking. J. Am. Coll. Cardiol. 56 (10 Suppl): S43-S78.
8. Garg, U.C., and Hassid, A. (1989). Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of culured rat vascular smooth muscle cells. J. Clin. Invest. 83, 1774-1777. (Pubitemid 19124139)
9. Haudenschild, C.C. (1989). Pathogenesis of restenosis. Z. Kar-diol. 78, 28-34. (Pubitemid 19223447)
10. Hilliard, A.A., From, A.M., Lennon, R.J., et al. (2010). Percutaneous revascularization for stable coronary artery disease: temporal trends and impact of drug-eluting stents. JACC Cardiovasc. Interv. 3, 172-179.
11. Holmes, D.R. Jr., Kereiakes, D.J., Garg, S., et al. (2010).Stent thrombosis. J. Am. Coll. Cardiol. 56, 1357-1365.
12. Kolpakov, V., Gordon, D., and Kulik, T.J. (1995). Nitric-oxide generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ. Res. 76, 305-309.
13. McCarthy, H.O., Coulter, J.A., Robson, T., and Hirst, D.G. (2008). Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. J. Pharm. Pharmacol. 60, 999-1017.
14. Muhs, A., Heublein, B., Schletter, J., et al. (2003). Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation. Hum. Gene Ther. 14, 375-384.
15. Myers, P.R., Webel, R., Thondapu, V., et al. (1996). Restenosis is associated with decreased coronary artery nitric oxide syn-thase. Int. J. Cardiol. 55, 183-191. (Pubitemid 26246916)
16. Pavlides, G.S., Barath, P., Maginas, A., et al. (1997). Intramural drug delivery by direct injection within the arterial wall: first clinical experience with a novel intracoronary delivery-infiltrator system. Cathet. Cardiovasc. Diagn. 41, 287-292. (Pubitemid 27283812)
17. Radomski, M.W., Palmer, R.M. and Moncada, S. (1990). An L-ar-ginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. U.S.A. 87, 5193-5197.
18. Reimers, B., Moussa, I., Akiyama, T., et al. (1998). Persistent high restenosis after local intrawall delivery of long-acting steroid before coronary stent implantation. J. Invasive Cardiol. 10, 323-331. (Pubitemid 128708967)
19. Ross, R. (1999). Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115-126.
20. Schaffer, M.R., Tantry, U., Gross, S.S., et al. (1996). Nitric oxide regulates wound healing. J. Surg. Res. 63, 237-240. (Pubitemid 26197729)
21. Serruys, P.W., de Jaegere, P., Kiemeneij, F., et al. (1994). A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med. 331, 489-495. (Pubitemid 24256751)
22. Sharif, F., Hynes, S.O., Cooney, R., et al. (2008). Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits rest-enosis. Mol. Ther. 16, 1674-1680.
23. Thornton, F.J., Schäffer, M.R., Witte, M.B., et al. (1998). Enhanced collagen accumulation following direct transfection of the in-ducible nitric oxide synthase gene in cutaneous wounds. Biochem. Biophys. Res. Commun. 246, 654-659. (Pubitemid 28420914)
24. V̈ane, J.R., Anggárd, E.E., and Botting, R.M. (1990). Regulatory functions of the vascular endothelium. N. Engl. J. Med. 323, 27-36. (Pubitemid 20209469)
25. Von der Leyen, H.E., and Chew, N. (2005). NOS gene transfer and treatment of restenosis: from bench to bedside. Eur. J. Clin. Pharmacol. 62, 83-89.
26. Von der Leyen, H.E., and Dzau, V.J. (2001). Therapeutic potential of nitric oxide synthase genemanipulation. Circulation 103, 2760-2765. (Pubitemid 32538794)
27. Von der Leyen, H.E., Gibbons, G.H., Morishita, R., et al. (1995). Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial-cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. U.S.A. 92, 1137-1141.
28. Yamasaki, K., Edington, H.D., McClosky, C., et al. (1998). Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J. Clin. Invest. 101, 967-971. (Pubitemid 28125274)
29. Zhong, H., Matsui, O., Xu, K., et al. (2009). Gene transduction into aortic wall using plasmid-loaded cationized gelatin hydrogel-coated polyester stent graft. J. Vasc. Surg. 50, 1433-1443.